The company
Cue Biopharma, Inc.
CUE · Nasdaq
CUE stood above a rising 150-day average in 23 of the last 52 weekly readings, and has been out of that trend for the last 1 week. It is 34.3% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).
Statistics
- Rotation
- Just dropped out
- Weeks in an uptrend
- out for 1
- Industry in uptrend
- 16% -15 in 4 wk
- Insider buys, 12 months
- $199K
- Insider sales, 12 months
- $4.5M
- Officials’ trades on record
- 0
- Institutions holding
- 47 (-4)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 23 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Sumita RayChief Legal Compliance Officer | sold | 1,844at $28.05 | 12 Oct 2026filed 14 Oct 2026 |
| Shao-Lee LinChief Executive Officer | sold | 10,000at $27.50 | 12 Oct 2026filed 14 Oct 2026 |
| Shao-Lee LinChief Executive Officer | sold | 1,087at $28.05 | 12 Oct 2026filed 14 Oct 2026 |
| Michael Vincent MeluzioVP, Prin. Accounting Officer | sold | 1,144at $28.05 | 12 Oct 2026filed 14 Oct 2026 |
| Sumita RayChief Legal Compliance Officer | sold | 2,383at $29.37 | 13 Aug 2026filed 17 Aug 2026 |
| Sumita RayChief Legal Compliance Officer | sold | 6,442at $30.35 | 13 Aug 2026filed 17 Aug 2026 |
| Sumita RayChief Legal Compliance Officer | sold | 4at $31.13 | 13 Aug 2026filed 17 Aug 2026 |
| Shao-Lee LinChief Executive Officer | sold | 5,423at $27.19 | 13 Aug 2026filed 14 Aug 2026 |
| Shao-Lee LinChief Executive Officer | sold | 2,375at $28.11 | 13 Aug 2026filed 14 Aug 2026 |
| Shao-Lee LinChief Executive Officer | sold | 10,460at $29.48 | 13 Aug 2026filed 14 Aug 2026 |
| Michael Vincent MeluzioVP, Prin. Accounting Officer | sold | 1,519at $29.37 | 13 Aug 2026filed 17 Aug 2026 |
| Michael Vincent MeluzioVP, Prin. Accounting Officer | sold | 4,106at $30.35 | 13 Aug 2026filed 17 Aug 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| Bleichroeder LPreduced · filed 13 Aug 2026 | 370,682$11.7M | -6,448,482−94.6% |
| Driehaus Capital Management LLCnew · filed 14 Aug 2026 | 292,144$9.2M | +292,144 |
| VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026 | 161,700$5.1M | -2,295,752−93.4% |
| Ikarian Capital, LLCnew · filed 14 Aug 2026 | 104,364$3.3M | +104,364 |
| Tetragon Partners GP Ltdnew · filed 13 Aug 2026 | 93,819$3.0M | +93,819 |
| STEMPOINT CAPITAL LPnew · filed 14 Aug 2026 | 66,995$2.1M | +66,995 |
| BlackRock, Inc.reduced · filed 7 Aug 2026 | 57,807$1.8M | -391,354−87.1% |
| ADAR1 Capital Management, LLCnew · filed 14 Aug 2026 | 55,193$1.7M | +55,193 |
| Lion Point Capital, LPreduced · filed 14 Aug 2026 | 52,928$1.7M | -2,149,926−97.6% |
| Squadron Capital Management LLCnew · filed 14 Aug 2026 | 50,000$1.6M | +50,000 |
News
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.